GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

The list for the next round of medicines that will ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

GlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a condition with no approved therapies and a lengthy list of failed drug ...

The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion. Wide-moat GSK’s third-quarter earnings aligned with our ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

GSK plans to invest $800 million in its East ... not yet approved by the Food and Drug Administration, known as Multiple Antigen Presenting System (MAPS). The renovations include expanding ...

Cautions Lower Revenue For 2024 GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines and HIV drugs show growth. Vandana Singh ...

Within a relatively short period, Zantac became the top-selling drug globally ... wrongdoing in these matters. Overall GSK ranks 7th on Jim Cramer's list of super micro computer and other stocks ...